Early and sustained improvements of lung clearance index from two to sixteen weeks of elexacaftor/tezacaftor/ivacaftor therapy in patients with cystic fibrosis-a real world study.

Front Pharmacol · 2023 · PMC10030732 · PMID 36969845

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

At week 16, the changes of the two parameters LCI and ppFEV1 compared to baseline showed a trend to correlate with each other, but without statistical significance (r = −0.375, p = 0.071).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.